Navigation Links
Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Amgen (NASDAQ: AMGN) today announced the results of the "145 study", a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of Aranesp(R) (darbepoetin alfa) in 600 previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving platinum-containing chemotherapy. The study demonstrated no statistically significant difference in risk of death (overall survival Aranesp compared to placebo Hazard Ratio (HR): 0.93, 95% CI: 0.78 to 1.11) or investigator determined progression-free survival (HR: 1.02, 95% CI: 0.86 to 1.21).

The study demonstrated a significant change in hemoglobin concentration from baseline in favor of Aranesp (a co-primary endpoint). Aranesp-treated patients also experienced a significantly lower risk of blood transfusions (HR: 0.40, 95% CI: 0.29 to 0.55). The overall safety profile, including thromboembolic events, was consistent with that described in the U.S. label.

"The 145 study is a component of Amgen's ongoing pharmacovigilance program designed to evaluate the effect of Aranesp on long-term survival in patients with chemotherapy-induced anemia. This study had higher initiation and maintenance hemoglobin targets (Hb less than or equal to 13 g/dl) than in the U.S. label," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "These results contribute to the growing body of evidence on ESA safety, reinforcing the neutral impact of ESAs on survival in cancer patients suffering from chemotherapy-induced anemia."

Amgen initiated the SCLC study in 2002 after results from a previous Phase 3 study showed a trend towards improved survival in patients with lung cancer. The 145 study was designed to evaluate whether increasing or maintaining hemoglobin concentrations with Aranesp, when administered with platinum-containing chemotherapy in patien
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
(Date:9/2/2014)... , Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present at ... Rodman & Renshaw 16 th ... ) Tuesday, September 9, 2014 at 9:10 a.m. ...
(Date:9/2/2014)... Sept. 2, 2014  Amgen (NASDAQ: ... of a Marketing Authorization Application (MAA) to ... centralized procedure for talimogene laherparepvec seeking approval ... that is regionally or distantly metastatic. Talimogene laherparepvec ... an intralesional injection that is designed to ...
(Date:9/2/2014)... SAN CARLOS, Calif. , Sept. 2, 2014 /PRNewswire/ ... a leader in synthetic biology, today announced that it ... Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: ... an enhanced production process for a specific family of ... manufacturing operations in France . This ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
... WaferGen Biosystems, Inc. (OTCBB:WGBSE), a leading developer of state-of-the-art ... second quarter ended June 30, 2011."During the second quarter, ... commercialize the SmartChip Real-Time PCR System.  We accomplished that ... placement financing of $30.6 million in equity and debt ...
... RANCHO CORDOVA, Calif., Sept. 12, 2011 ThermoGenesis Corp. (NASDAQ: ... and services that process and store adult stem cells in ... quarter and all of fiscal 2011. For the ... $5.4 million, compared to $7.2 million in the fourth quarter ...
Cached Medicine Technology:WaferGen Reports Second Quarter 2011 Financial Results 2WaferGen Reports Second Quarter 2011 Financial Results 3WaferGen Reports Second Quarter 2011 Financial Results 4WaferGen Reports Second Quarter 2011 Financial Results 5WaferGen Reports Second Quarter 2011 Financial Results 6WaferGen Reports Second Quarter 2011 Financial Results 7WaferGen Reports Second Quarter 2011 Financial Results 8ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 2ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 3ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 4ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 5ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 6
(Date:9/2/2014)... (PRWEB) September 02, 2014 Anti-aging ... products and services such as anti-wrinkle treatments and ... based treatments, and breast augmentation becoming much sought ... by U.S.-based market intelligence firm Transparency Market Research, ... products will grow to USD 191.7 billion by ...
(Date:9/2/2014)... CITY, GA (PRWEB) September 02, 2014 Last ... whole new level with the launch of a luxurious line ... to announce that the SEA ISLAND COTTON Socks are joining ... compression level, giving more people the comfort of natural cotton ... COTTON Socks, they are surprised to find socks as soft ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Alliance Strategies ... and multi-channel email marketing is pleased to announce it ... Firearms & Freedom as well as ... represent more than one million concerned Americans who can ... , “We are honored to continue providing our ...
(Date:9/2/2014)... What happens when you are hospitalized, but your ... arrive at the office for follow-up care, but ... about your hospital stay? Missing or incomplete ... (PCPs) can contribute to poor experiences and lead ... study shows that implementing guidelines can improve hospitals, ...
(Date:9/2/2014)... health risks, including heart disease and diabetes, but University ... mitigate one often-overlooked risk: not buckling up in the ... Jacobson, a professor of computer science and of mathematics, ... a decrease in seatbelt usage. However, these effects can ... "Primary seatbelt laws lead to increased use of seatbelts," ...
Breaking Medicine News(10 mins):Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2
... bit relaxed now. Genosis Inc, a US firm, has developed ... test has his and hers components a screening test ... the concentration of motile sperm, and a test for women ... ,The availability of the two-in-one test helps drive ...
... Depressed? Consider marriage as an option please, a pair of ... happier you could be after marriage . And never mind ... to benefit, claim Adrianne Frech, a sociology graduate student at ... ,They looked at a sample of 3,066 men and women ...
... WASHINGTON, D.C. A first-of-its-kind study presented at the 54th ... molecular imaging and nuclear medicine professionals , declares that ... tumor patients' response to treatment is a powerful predictor ... to the possibility that brain tumor patients may live ...
... of Preferred Provider Organizations (AAPPO) is launching a new ... care to those patients diagnosed with diabetes as ... An industry leader, AAPPO today kicked off its new ... take Action, Champion better care, and empower their patients ...
... announced today that HHS has awarded a contract for $500 ... manufacture and deliver 20 million doses of a next generation ... would be recommended in the event of a smallpox outbreak ... immune systems. The full supply of the vaccine will be ...
... Mental Health Services Administration (SAMHSA) today announced that ... three years to the state of Iowa ... The first year award is $400,000. This grant ... intervention and treatment services for youth suicide prevention ...
Cached Medicine News:Health News:Fertility Test at Home Possible With a New Kit 2Health News:Marriage Could Lift One Out of Depression, New Study 2Health News:Brain Tumor Patients Survival Depends on Predicting Treatment Responses Earlier 2Health News:AAPPO Launches ACT on Diabetes Initiative to Promote Improved Diabetes Care 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:Iowa to Receive Grant Funding for Youth Suicide Prevention, Early Intervention 2
... Minimize Patient Trauma and Increase Staff Protection ... (10 Fr, 12 Fr, 14 Fr, 16 ... Suction Catheters with Contro-Vac Valves and DeLee ... potential for inflammation,during suctioning. Each catheter utilizes ...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Sterile, Coil Packed Suction Catheter Mini Tray with (2) Walleted SAFESKIN PURPLE NITRILE Latex-Free Exam Gloves...
Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
Medicine Products: